Vectiopep is the best spin-off of the University of Tartu in 2024! We are grateful for this recognition by the City of Tartu and the University of Tartu! Last week was the entrepreneurship week in Tartu and the University of Tartu presented the spin-off of the year to the citizens. Now, the only thing that remains to do is to live up to the title 😀 https://lnkd.in/eHA5_uqp
Vectiopep
Biotechnology Research
We develop cancer immunotherapy with our unique mRNA delivery technology
About us
Vectiopep is developing peptide-based nucleic acid delivery technology. Combined with the new generation mRNA therapeutics, we empower the body's immune system to fight cancer. Vectiopep is a privately-held biotechnology company, founded by a group of researchers who have more than 10 years of expertise in developing and optimizing delivery technologies for nucleic acids..
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Tartu
- Type
- Privately Held
- Founded
- 2022
Locations
-
Primary
Get directions
Tartu, EE
Employees at Vectiopep
Updates
-
With great honor we announce that the European Innovation Council has awarded Vectiopep with the prestigious SEAL OF EXCELLENCE certificate. For our team, this recognizes our commitment to innovation and verifies our potential to significantly impact cancer treatment with therapeutic mRNA. The award proves the quality and value of our work and opens doors for new opportunities. We're inviting investors to contribute to new and efficient cancer treatment solutions. Stay tuned for more information! #SealOfExcellence #therapeuticmRNA
-
-
Vectiopep announces successful raising of pre-seed investment!
Today, we announce our €450k pre-seed funding from angel investor syndicate led by Ivo Remmelg and Dag Nurm, and UniTartu Ventures. A year ago, we conceptualized an idea to develop a solution for therapeutic delivery for #cancerimmunotherapy. At that time, it was a passion in the academic setting, and an outline for a research publication. For the Vectiopep team, today marks the first step in a larger mission to advance the technology to clinical application!
-